400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
2024-02-08
临床前阶段细胞疗法研发商
医药研发/制造
化学&生物药
Viking Global Investors;
Viking Global Investors;
鱼鹰资管;
鱼鹰资管;
The Column Group;
洲嶺资本;
Schroders Capital;
Willett Advisors LLC;
Ysios Capital Partners;
Euclidean Capital;
Symbiosis;
Alexandria Venture Investments;
Berkeley Frontier Fund;
Sphera Biotech Master Fund;
Spur Capital Partners;
UCB Ventures;
UC Investments
动脉网2026-03-12
动脉网2026-03-12
2026-03-11
动脉网2026-03-11
PR Newswire2026-03-11
PR Newswire2026-03-11
2026-03-11
动脉网2026-03-11
startupticker2026-03-11
GlobeNewswire2026-03-10